
0:28Drug trial using Ozempic's active ingredient to slow Alzheimer's fails
A drug trial using the active ingredient in Ozempic to slow the progression of Alzheimer's disease has failed. Drugmaker Novo Nordisk says semaglutide led to improvements but did not delay the progression of Alzheimer's.